MedTrace Logo

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

NCT05619536 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-10-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when dosed by subcutaneous (SQ) administration as a single dose to healthy Japanese adult subjects.

Conditions

  • Healthy

Interventions

COMBINATION_PRODUCT

CD388 Injection

CD388 liquid for injection

DRUG

Saline placebo

Sterile normal saline for injection

Sponsors & Collaborators

  • Janssen Pharmaceuticals

    collaborator INDUSTRY

  • Cidara Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Ozlem Equils, MD · Cidara Therapeutics Inc.

  • Youngjun Kim, MD · Altasciences Clinical Los Angeles, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-18
Primary Completion
2023-07-14
Completion
2023-07-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05619536 on ClinicalTrials.gov